The X Linked Adrenoleukodystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“X Linked Adrenoleukodystrophy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the X Linked Adrenoleukodystrophy Market.

Some of the key takeaways from the X Linked Adrenoleukodystrophy Pipeline Report:

• Companies across the globe are diligently working toward developing novel X Linked Adrenoleukodystrophy treatment therapies with a considerable amount of success over the years. 
• X Linked Adrenoleukodystrophy companies working in the treatment market are Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others, are developing therapies for the X Linked Adrenoleukodystrophy treatment 

• Emerging X Linked Adrenoleukodystrophy therapies such as – ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others are expected to have a significant impact on the X Linked Adrenoleukodystrophy market in the coming years.   
• In November 2021, Minoryx Therapeutics reported that at the 146th Annual Meeting of the American Neurological Association (ANA) 2021, more data from its Phase 2/3 ADVANCE clinical trial had been presented in a poster presentation
• In January 2020, Leriglitazone was given fast track approval by the US FDA to treat all types of X-linked adrenoleucodystrophy
• In September 2020, Toleriglitazone was given the Rare Paediatric Disease (RPD) classification by the US FDA for the treatment of X-linked adrenoleucodystrophy, according to a statement from Minoryx Therapeutics

X Linked Adrenoleukodystrophy Overview

The neurological system and the adrenal glands, which are tiny glands that sit on top of each kidney, are both impacted by the hereditary condition known as X Linked Adrenoleukodystrophy (X-ALD). Progressive loss of the fatty sheathing (myelin) that surrounds the nerves in the brain and spinal cord is a common symptom of this disease.

Get a Free Sample PDF Report to know more about X Linked Adrenoleukodystrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/x-linked-adrenoleukodystrophy-x-ald-pipeline-insight

Emerging X Linked Adrenoleukodystrophy Drugs Under Different Phases of Clinical Development Include:

• ABX-002: Autobahn Therapeutics
• VK0214: Viking Therapeutics
• SBT101: SwanBio Therapeutics
• PXL065: Poxel SA
• PXL770: Poxel SA
• Leriglitazone : Minoryx Therapeutics
• OP101 : Orpheris
• Leriglitazone (MIN102): Minoryx Therapeutics 

Route of Administration

X Linked Adrenoleukodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

X Linked Adrenoleukodystrophy Pipeline Therapeutics Assessment

• X Linked Adrenoleukodystrophy Assessment by Product Type
• X Linked Adrenoleukodystrophy By Stage and Product Type
• X Linked Adrenoleukodystrophy Assessment by Route of Administration
• X Linked Adrenoleukodystrophy By Stage and Route of Administration
• X Linked Adrenoleukodystrophy Assessment by Molecule Type
• X Linked Adrenoleukodystrophy by Stage and Molecule Type

DelveInsight’s X Linked Adrenoleukodystrophy Report covers around 3+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further X Linked Adrenoleukodystrophy product details are provided in the report. Download the X Linked Adrenoleukodystrophy pipeline report to learn more about the emerging X Linked Adrenoleukodystrophy therapies

Some of the key companies in the X Linked Adrenoleukodystrophy Therapeutics Market include:

Key companies developing therapies for X Linked Adrenoleukodystrophy are – AstraZeneca, Cipla Inc., Abbott, Bayer AG, Merck KGaA, GlaxoSmithKline plc, agtc, bluebird bio, MINORYX THERAPEUTICS SL, SwanBio Therapeutics, Inc., Viking Therapeutics, Novartis AG, Sanofi, Pfizer Inc., Sumitomo Corporation, Johnson & Johnson Private Limited, and others.

X Linked Adrenoleukodystrophy Pipeline Analysis:

The X Linked Adrenoleukodystrophy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of X Linked Adrenoleukodystrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for X Linked Adrenoleukodystrophy Treatment.
• X Linked Adrenoleukodystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• X Linked Adrenoleukodystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the X Linked Adrenoleukodystrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about X Linked Adrenoleukodystrophy drugs and therapies

X Linked Adrenoleukodystrophy Pipeline Market Drivers

• Increasing awareness towards genetic diseases coupled with genetic counseling, rise in the number of R&D activities are some of the important factors that are fueling the X Linked Adrenoleukodystrophy Market.

X Linked Adrenoleukodystrophy Pipeline Market Barriers

• However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the X Linked Adrenoleukodystrophy Market growth.

Scope of X Linked Adrenoleukodystrophy Pipeline Drug Insight    

• Coverage: Global
• Key X Linked Adrenoleukodystrophy Companies: Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others
• Key X Linked Adrenoleukodystrophy Therapies: ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others
• X Linked Adrenoleukodystrophy Therapeutic Assessment: X Linked Adrenoleukodystrophy current marketed and X Linked Adrenoleukodystrophy emerging therapies
• X Linked Adrenoleukodystrophy Market Dynamics: X Linked Adrenoleukodystrophy market drivers and X Linked Adrenoleukodystrophy market barriers 

Request for Sample PDF Report for X Linked Adrenoleukodystrophy Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services